Purpose:: Topical corticosteroids (TS) are a treatment for atopic dermatitis (AD) and psoriasis (Ps). We assessed whether use of a TS under conditions designed to enhance adherence would be effective in patients who "failed" TS in the outpatient setting.

Methods:: Individuals with treatment-resistant Ps or AD were recruited (AD, n = 12; Ps, n = 12). Six participants were randomized to each of 2 groups of desoximetasone 0.25% spray alone (n = 6) or desoximetasone spray plus twice-daily phone call reminders to use the medication. Disease severity was assessed.

Results:: In treatment-resistant Ps patients, desoximetasone spray, with reminders, resulted in statistically significant improvement in all outcome measures. In treatment-resistant AD patients, there was statistically significant improvement in some assessments. Despite the very small sample size and short evaluation time, statistically significant changes were detected in this cohort. This is evidence of the large effect size of TS for Ps and AD when the treatment is used.

Conclusions:: Patients with "treatment-resistant" Ps and AD generally responded well to the use of desoximetasone spray in the trial setting. This may be due to better adherence in the study environment or patients' preference for the spray vehicle. Patient reminders contributed to improved clinical outcomes in Ps and AD patients with "treatment-resistant" disease.

Download full-text PDF

Source
http://dx.doi.org/10.1177/1203475418818082DOI Listing

Publication Analysis

Top Keywords

desoximetasone spray
16
atopic dermatitis
8
treatment-resistant patients
8
statistically improvement
8
patients "treatment-resistant"
8
spray
6
desoximetasone
5
patients
5
psoriasis atopic
4
dermatitis "resistant"
4

Similar Publications

Physiologically based pharmacokinetic (PBPK) models are widely accepted tools utilised to describe and predict drug pharmacokinetics (PK). This includes the use of dermal PBPK models at the regulatory level including virtual bioequivalence (VBE) studies. The current work considers the Topicort Spray formulation, which contains 0.

View Article and Find Full Text PDF

Adherence to topical treatment can improve treatment-resistant moderate psoriasis.

Cutis

February 2020

Center for Dermatology Research, Departments of Pathology and Social Sciences and Health Policy, Department of Dermatology, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA.

Most patients with psoriasis have limited disease that should be manageable with topical treatment. However, psoriasis often is resistant to topical treatment. The aim of our study was to determine if patients using psoriasis-resistant topical treatments can be effectively treated with topicals under conditions promoting adherence.

View Article and Find Full Text PDF

A review of topical corticosteroid sprays for the treatment of inflammatory dermatoses.

Dermatol Online J

August 2019

Center for Dermatology Research, Department of Dermatology, Wake Forest School of Medicine, Winston-Salem, NC.

Article Synopsis
  • Topical corticosteroid treatments vary in their delivery methods, with sprays potentially enhancing patient convenience and adherence while maintaining strong efficacy against skin conditions.
  • In clinical trials, clobetasol propionate spray showed significant improvement in skin severity for psoriasis compared to the control, with 87% of subjects achieving a low disease severity score within two weeks.
  • Desoximetasone and betamethasone sprays also demonstrated effectiveness in reducing symptoms, while triamcinolone showed clear benefits for inflammatory skin conditions, with similar adverse effects reported across the different corticosteroid sprays.
View Article and Find Full Text PDF

: To determine if resistance to topical treatments can be overcome under conditions promoting adherence.: Twelve psoriasis patients treated with topical 0.25% desoximetasone spray were randomized to either twice daily phone call reminders or no phone call and were treated for 2 weeks.

View Article and Find Full Text PDF

Purpose:: Topical corticosteroids (TS) are a treatment for atopic dermatitis (AD) and psoriasis (Ps). We assessed whether use of a TS under conditions designed to enhance adherence would be effective in patients who "failed" TS in the outpatient setting.

Methods:: Individuals with treatment-resistant Ps or AD were recruited (AD, n = 12; Ps, n = 12).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!